Vistagen Therapeutics Inc - VTGN STOCK NEWS

Vistagen (Nasdaq: VTGN) has announced the granting of a new U.S. patent for its PH80 nasal spray, designed for migraine treatment, with protection extending until at least 2040. This investigational product offers a rapid-onset mechanism of action, distinguishing it from current CNS treatments. Migraine affects around 40 million U.S. adults annually, highlighting a significant need for effective therapies. Vistagen's recent acquisition of Pherin Pharmaceuticals grants it complete ownership of intellectual property rights for five pherine candidates, including PH80. The company aims to innovate CNS disorder treatments.

Vistagen (Nasdaq: VTGN) has completed its acquisition of Pherin Pharmaceuticals, securing full ownership of PH94B and PH10, eliminating future royalty payments. The company is advancing its PH94B Phase 3 program for social anxiety disorder and has initiated a Phase 1 study for PH10 in major depressive disorder, which received FDA Fast Track designation. Research and development expenses decreased from $7.8 million to $6.9 million year-over-year, while net losses narrowed from $10.7 million to $9.8 million. Vistagen aims to explore multiple administration strategies for PH94B and anticipates announcing further developments in 2023.

Vistagen (NASDAQ: VTGN) announced a conference call scheduled for February 7, 2023, at 2:00 p.m. PT to discuss its fiscal year 2023 third quarter financial results, ending December 31, 2022. The call will provide updates on the company's efforts to transform treatment for CNS disorders, focusing on anxiety and depression. Vistagen is developing pherines, a new class of therapeutics aimed at faster relief with fewer side effects. The company emphasizes its commitment to improving mental health care with innovative treatment options.

Vistagen (Nasdaq: VTGN) has successfully acquired Pherin Pharmaceuticals, eliminating all future royalty obligations for its leading drug candidates, PH94B and PH10. PH94B is in Phase 3 for social anxiety disorder, while PH10 is in clinical development for major depressive disorder. This acquisition not only enhances Vistagen's portfolio, including three additional drug candidates, but also significantly improves the commercial outlook for these products. CEO Shawn Singh emphasized the strategic importance of this acquisition in advancing treatments for anxiety and depression, which affect millions.

Vistagen (NASDAQ: VTGN) has initiated a Phase 1 clinical trial for PH10, a pherine nasal spray targeting major depressive disorder (MDD). The trial's primary aim is to evaluate the safety and tolerability of PH10 in 12 healthy adult subjects, building on previous favorable results from three earlier studies, including a Phase 2A trial in Mexico. The study, expected to conclude by Q1 2023, is a stepping stone towards the company's Phase 2B development plans. PH10’s unique mechanism activates chemosensory neurons to produce rapid antidepressant effects without systemic uptake, potentially differentiating it from existing treatments.

Vistagen (Nasdaq: VTGN) announces the completion of the Phase 2 clinical trial for PH94B, aimed at treating adults with adjustment disorder with anxiety. This exploratory study was a U.S.-based, double-blind, placebo-controlled trial evaluating the efficacy, safety, and tolerability of PH94B over four weeks. The primary endpoint focused on anxiety level reduction, gauged via the Hamilton Anxiety Rating Scale. Topline results are expected by the end of Q1 2023, marking a significant milestone amid growing mental health challenges.

Vistagen (Nasdaq: VTGN) recently announced new patent filings with the U.S. Patent and Trademark Office and other countries to enhance commercial protection for its lead drug candidate, PH94B, aimed at treating adjustment disorder (AjD). This move follows a similar patent protection obtained for PH94B regarding social anxiety disorder (SAD) and PH10 for major depressive disorder (MDD). Additionally, the pending acquisition of Pherin Pharmaceuticals will expand Vistagen's patent portfolio and pipeline, including new drug candidates targeting various mental health disorders.

Vistagen (Nasdaq: VTGN) has announced a definitive agreement to acquire Pherin Pharmaceuticals, acquiring its pherine pipeline for approximately 12.4 million shares of common stock and a nominal cash amount. This acquisition will eliminate future royalty and milestone payments related to Vistagen’s existing drug candidates, PH94B and PH10, while adding three new drug candidates. The acquisition is expected to strengthen Vistagen’s position in addressing treatment gaps for anxiety and depression. The deal is subject to customary closing conditions and Pherin stockholder approval.

Vistagen (NASDAQ: VTGN) has received Fast Track designation from the FDA for its investigational nasal spray, PH10, aimed at treating major depressive disorder (MDD). This designation is intended to expedite development for drugs addressing serious conditions. PH10 has shown promising results in clinical studies, significantly reducing depressive symptoms within one week of treatment while avoiding common psychological side effects. With 21 million adults in the U.S. experiencing MDD annually, Vistagen aims to meet an urgent treatment need.